BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38287498)

  • 1. Genome-wide loss-of-function genetic screen identifies INSIG2 as the vulnerability of hepatitis B virus-integrated hepatoma cells.
    Fukuoka M; Kodama T; Murai K; Hikita H; Sometani E; Sung J; Shimoda A; Shigeno S; Motooka D; Nishio A; Furuta K; Tatsumi T; Yusa K; Takehara T
    Cancer Sci; 2024 Mar; 115(3):859-870. PubMed ID: 38287498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
    J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
    Murai K; Kodama T; Hikita H; Shimoda A; Fukuoka M; Fukutomi K; Shigeno S; Shiode Y; Motooka D; Higuchi Y; Miyakawa K; Suemizu H; Ryo A; Tahata Y; Makino Y; Yamada R; Sakamori R; Tatsumi T; Takehara T
    Hepatol Commun; 2022 Sep; 6(9):2474-2487. PubMed ID: 35608131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PreC/C gene-targeting RNA interference suppresses hepatitis B virus replication and expression in human hepatoma cells].
    Bian ZQ; Liu S; Liu MQ; Xiao A; Jiao Y; Yan WY; Zheng ZX
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(11):768-72. PubMed ID: 22781359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway.
    Duan X; Li S; Holmes JA; Tu Z; Li Y; Cai D; Liu X; Li W; Yang C; Jiao B; Schaefer EA; Fusco DN; Salloum S; Chen L; Lin W; Chung RT
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing.
    Zhou H; Wang X; Steer CJ; Song G; Niu J
    Hepatol Commun; 2022 Jul; 6(7):1652-1663. PubMed ID: 35338607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient.
    Kato Y; Tabata H; Sato K; Nakamura M; Saito I; Nakanishi T
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.
    Yu G; Chen X; Chen S; Ye W; Hou K; Liang M
    J Transl Med; 2016 May; 14(1):122. PubMed ID: 27150195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus X protein mediated suppression of miRNA-122 expression enhances hepatoblastoma cell proliferation through cyclin G1-p53 axis.
    Bandopadhyay M; Sarkar N; Datta S; Das D; Pal A; Panigrahi R; Banerjee A; Panda CK; Das C; Chakrabarti S; Chakravarty R
    Infect Agent Cancer; 2016; 11():40. PubMed ID: 27528885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
    Liu X; Hao R; Chen S; Guo D; Chen Y
    J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
    Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
    Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
    Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
    Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBV Integration-mediated Cell Apoptosis in HepG2.2.15.
    Hu X; Jiang J; Ni C; Xu Q; Ye S; Wu J; Ge F; Han Y; Mo Y; Huang D; Yang L
    J Cancer; 2019; 10(17):4142-4150. PubMed ID: 31417659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX9 represses hepatitis B virus replication through binding to HBV EnhII/Cp and inhibiting the promoter activity.
    Yang H; Zhou Y; Mo J; Xiang Q; Qin M; Liu W; Shang J; Yang Q; Xu W; Yang G; Tan Q; Wu K; Liu Y; Wu J
    Antiviral Res; 2020 May; 177():104761. PubMed ID: 32147495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter.
    Ibrahim MK; Abdelhafez TH; Takeuchi JS; Wakae K; Sugiyama M; Tsuge M; Ito M; Watashi K; El Kassas M; Kato T; Murayama A; Suzuki T; Chayama K; Shimotohno K; Muramatsu M; Aly HH; Wakita T
    J Virol; 2021 Jul; 95(15):e0076721. PubMed ID: 33980595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro infection of human hepatoma cells (HepG2) with hepatitis B virus (HBV): spontaneous selection of a stable HBV surface antigen-producing HepG2 cell line containing integrated HBV DNA sequences.
    Mabit H; Dubanchet S; Capel F; Dauguet C; Petit MA
    J Gen Virol; 1994 Oct; 75 ( Pt 10)():2681-9. PubMed ID: 7931154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
    Park US; Park SK; Lee YI; Park JG; Lee YI
    Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
    Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
    Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cell cycle on telomerase activity and on hepatitis B virus replication in HepG2 2.2.15 cells.
    Huang YQ; Wang LW; Yan SN; Gong ZJ
    Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):543-7. PubMed ID: 15567742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.